Akari Therapeutics (AKTX) vs Atossa Therapeutics (ATOS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Akari Therapeutics (AKTX) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 60.1% versus a loss of 86.4%. Over five years, ATOS leads with a -95.3% price change compared with -99.5% for AKTX. Akari Therapeutics is the larger company by market cap ($16.7 million vs $15.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | ATOS |
|---|---|---|
| Share price | $7.18 | $1.60 |
| Market cap | $16.70M | $15.92M |
| 1-day change | +7.00% | -8.86% |
| YTD return | -37.89% | -81.98% |
| 1-year return | -60.11% | -86.37% |
| 5-year return | -99.47% | -95.34% |
| EPS (TTM) | $0.00 | $-3.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-17.30M | $-34.77M |
| 52-week high | $29.32 | $14.85 |
| 52-week low | $3.02 | $1.59 |
| Distance from 52-week high | -75.51% | -89.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +255.15% | +1091.22% |
| Average volume | 58.54K | 68.00K |
| Shares outstanding | 2.33M | 9.98M |
| Employees | 5 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AKTX has outperformed ATOS by 26.3 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
AKTX vs ATOS FAQ
Which is bigger, Akari Therapeutics or Atossa Therapeutics?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $16.70M compared with $15.92M for Atossa Therapeutics (ATOS).
Which stock has performed better over the past year, AKTX or ATOS?
AKTX returned -60.11% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Atossa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.